Central Lung Tumors Eligible for Stereotactic Ablative Radiotherapy (SABR) Trials: Analysis of a Cohort Treated Using MR-Guided SABR

被引：0
|
作者：
Giraud, N. [1 ]
Schneiders, F. L. [1 ]
Palacios, M. A. [1 ]
de Koste, J. R. van Sornsen [1 ]
Sesan, S. [1 ]
机构：
[1] Amsterdam UMC, Amsterdam, Netherlands
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2041
引用
收藏
页码：E20 / E20
页数：1
相关论文
共 50 条
  • [21] Spatial Assessment of Dose Distributions for Patients with Lung Cancer Treated with Stereotactic Ablative Radiotherapy (SABR)
    Liu, D.
    Chen, D.
    Chetvertkov, M.
    Altman, M.
    Li, H.
    Wen, N.
    Glide-Hurst, C.
    Ajlouni, M.
    Levin, K.
    Movsas, B.
    Chetty, I.
    MEDICAL PHYSICS, 2012, 39 (06) : 3817 - 3817
  • [22] Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort
    Murray, L.
    Ramasamy, S.
    Lilley, J.
    Snee, M.
    Clarke, K.
    Musunuru, H. B.
    Needham, A.
    Turner, R.
    Sangha, V.
    Flatley, M.
    Franks, K.
    CLINICAL ONCOLOGY, 2016, 28 (01) : 4 - 12
  • [23] Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
    Binkley, Michael S.
    Shrager, Joseph B.
    Chaudhuri, Aadel
    Popat, Rita
    Maxim, Peter G.
    Shultz, David Benjamin
    Diehn, Maximilian
    Loo, Billy W., Jr.
    RADIATION ONCOLOGY, 2016, 11
  • [24] Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
    Michael S. Binkley
    Joseph B. Shrager
    Aadel Chaudhuri
    Rita Popat
    Peter G. Maxim
    David Benjamin Shultz
    Maximilian Diehn
    Billy W. Loo
    Radiation Oncology, 11
  • [25] Dosimetric Predictors of Local Control after Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors: A Secondary Analysis of a Phase II Prospective Trial of Individualized SABR (iSABR)
    Wu, Yufan Fred
    Lau, Brianna
    Fu, Jie
    Skinner, Lawrie
    Gensheimer, Michael
    Gee, Harriet
    Diehn, Maximilian
    Loo, Billy
    Chin, Alex
    Vitzthum, Lucas
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (09): : S16 - S16
  • [26] Stereotactic ablative body radiotherapy (SABR) for multiple lung tumours: hazardous or harmless?
    Allos, B.
    Carruthers, H.
    Harrop, V.
    Stange, D.
    Misheva, T.
    Stevenson, R.
    Watkins, S.
    Ghafoor, Q.
    LUNG CANCER, 2018, 115 : S58 - S58
  • [27] Efficacy and safety profile of Stereotactic Ablative Radiotherapy (SABR) for multiple lung primaries
    Littlejohns, A.
    Janjua, T.
    Murray, P.
    Jain, P.
    Clarke, K.
    Dickinson, P.
    Teo, M.
    Saha, A.
    Franks, K.
    Sun, F.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S542 - S542
  • [28] Stereotactic Ablative Radiotherapy (SABR) for Non-Small Cell Lung Cancer
    Iyengar, Puneeth
    Westover, Kenneth
    Timmerman, Robert D.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 34 (06) : 845 - 854
  • [29] Clinical implementation of stereotactic ablative radiotherapy (SABR) for lung early stage NSCLC
    Routsis, D.
    Dean, J.
    Archer, S.
    Ferriera, C.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S304 - S304
  • [30] Quantification of interplay and gradient effects for lung stereotactic ablative radiotherapy (SABR) treatments
    Tyler, Madelaine K.
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2016, 17 (01): : 158 - 166
12345